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Abstract
Introduction: For people living with HIV, the first antiretroviral treatment (ART) regimen offers the best chance for a good
virological response. Early identification of those unlikely to respond to first-line ART could enable timely intervention and
increase chances of a good initial treatment response. In this study we assess the extent to which the HIV RNA viral load (VL)
at 1 and 3 months is predictive of first-line treatment outcome at 6 months.
Methods: All previously ART-naive individuals starting ART at two London centres since 2000 with baseline (−180 to 3 days)
VL >500 c/mL had a VL measurement between 6 and 12 months after starting ART, and at least one at month 1 (4–60 days)
or month 3 (61–120 days) were included. Lack of treatment response was defined as (i) VL >200 copies/mL at 6 months or (ii)
VL >200 copies/mL at 6 months or simultaneous switch in drugs from at least two different drug classes before 6 months.
The association with VL measurements at 1 and 3 months post-ART; change from pre-ART in these values; and CD4 count
measurements at 1 and 3 months were assessed using logistic regression models. The relative fit of the models was
compared using the Akaike information criterion (AIC).
Results: A total of 198 out of 3258 individuals (6%) experienced lack of treatment response at 6 months (definition i), increasing
to 511 (16%) for definition (ii). Those with a 1-month (day 4–60 window) VL of <1000, 1000–9999, 10,000–99,999 and
>100,000 copies/ml had a 4%, 8%, 23% and 24% chance, respectively, of subsequently experiencing treatment non-response
at 6 months (definition (i)). When considering the 3-month (day 61–120 window) VL, the chances of subsequently experiencing
treatment non-response were, respectively, 3%, 25%, 67% and 75%. Results were similar for definition (ii).
Conclusions: Whilst 3-month VL provides good discrimination between low and high risk of treatment failure, 1-month VL
does not. Presence of a VL >10,000 copies/ml after 3 months of ART is a cutoff above which individuals are at a sufficiently
higher risk of non-response that they may be considered for intervention.
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Introduction
For people living with HIV, the first antiretroviral therapy
(ART) regimen offers the best chance for a good virological
response, which, if achieved, then minimizes the chance of
developing resistance [1,2]. Ability to attain a strong initial
response, typically defined after six months of ART, is
associated with long-term virological suppression.
Although in the UK the proportion achieving a good initial
virological response to ART is high [1], there is still a small
proportion who do not. Earlier identification (within the
first three months of ART) of those with a higher probability
of not achieving a successful initial response to ART could
allow for early interventions to improve the probability that
virological suppression will be achieved and prevent the
development of resistance.
Several studies conducted to evaluate predictors of vir-
ological response to ART in treatment-naive patients have
found an association between higher pre-ART HIV RNA viral
load (VL) and increased risk of treatment failure by
6–12 months [3–9]. Furthermore, a few studies have eval-
uated the association between VL levels in the first
1–2 months of ART and subsequent virological response
[3,8,9]. However, most of these studies considered the
earlier ART calendar period (pre-2000), and results may
not be applicable to those starting ART today, with newer,
better tolerated or more effective drugs.
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This study assesses the ability of the very early VL
response to first ART at 1 and 3 months to predict subse-
quent initial treatment outcome at 6 months in a routine
clinical setting among people starting ART from 2000 to
2014.
Methods
Individuals included in this study were HIV-positive atten-
dees aged ≥18 years at two outpatient clinics in London:
the Ian Charleson Day Centre at the Royal Free Hospital and
the Mortimer Market Centre. Information was collected
from medical notes and electronic records and included
demographics, ART treatment history and all VL and CD4
count measurements.
Those included were previously ART-naive and starting
an ART regimen consisting of three or more antiretrovir-
als, including exactly two nucleoside reverse transcriptase
inhibitors (NRTIs) and exactly one of a ritonavir-boosted
protease inhibitor (PI), non-NRTI (NNRTI), raltegravir or
maraviroc between 1 January 2000 and 1 October 2015.
In addition, individuals were required to have a baseline
VL >500 copies/mL (to ensure previously treated indivi-
duals were not included) measured in a window of −180
to +3 days from the start date of the first regimen
(“baseline”); a 6 month VL, defined as the first VL
between 6 and 12 months after starting ART, and at
least one VL measurement at 1 or 3 months. Windows
from day 4 to day 60 and from day 61 to day 120 were
used, respectively, to define 1 month and 3 month mea-
sures. If more than one measurement was recorded in
these windows, that closest to 1 and 3 months, respec-
tively, was used.
The outcome of treatment non-response was defined in
two ways: (i) 6 month VL >200 copies/mL or (ii) either
6 month VL >200 copies/mL or simultaneous switch/stop
of antiretrovirals of at least two drug classes by 6 months. A
cutoff of 200 copies/ml was used as low-level blips likely do
not constitute treatment failure. The inclusion of treatment
switch/stop was intended to capture situations where
treatment was changed due to perceived virological failure
prior to 6 months. Switch of drugs from two or more
classes was required to exclude switches made solely for
toxicity reasons. Only switches and stops made 28 days to
6 months after starting ART were included.
The unadjusted and adjusted associations of VL, change
in VL from baseline and CD4 count, at months 1 and 3
(predictor variables), with treatment response at 6 months
(outcome variable) was assessed graphically and using
logistic regression. Current VL was considered as a catego-
rical variable (<200, 200–499, 500–999, 1000–9999,
10,000–99,999 and ≥100,000 copies/ml) and as a continu-
ous variable on the logarithmic10 scale. Multivariable ana-
lyses were adjusted for age (continuous), ethnicity (white,
black or other), gender/likely HIV acquisition route (men
who have sex with men, men who have sex with women,
women) and treatment type (1 NNRTI+2 NRTI, other). To
compare the predictive ability (goodness-of-fit) between
the different measures, the Akaike Information Criterion
(AIC) for the models were calculated [10] restricting analy-
sis to attendees with all measures recorded, a lower value
indicates better fit.
Two sensitivity analyses were performed. First, treatment
non-response was re-defined changing the cutoff from 200
to 50 copies/ml. Second, analyses were repeated on the
subset who started ART in the later years of 2008–2014.
All data analyses were performed using STATA version
SE13. The Royal Free HIV Cohort and the Mortimer Market
HIV cohort have received favourable ethical review by the
Royal Free Hospital and Medical School, and the Camden
and Islington NHS Research Ethics Committees. Individual
participant consent was not required on the premise that
the analysis was conducted on an anonymized data set. The
study did not receive external funding.
Results and discussion
Of 6059 individuals starting ART between 1 January 2000
and 30 October 2015, 1366 (22%) had a missing pre-ART VL,
536 (9%) had a baseline VL ≤500 copies/ml, 539 (9%) did
not have a VL measurement at 6 months post-ART and 360
(6%) did not have a VL measured at either 1 or 3 months
post-ART. Therefore, 3258 individuals (54% of all those
recorded as starting ART) were included; 2938 (90%) and
2223 (68%) had VL measurements after 1 and 3 months of
ART, respectively; 1903 (58%) had a measurement at both
time points.
Most individuals were men (2583; 79%), of white ethni-
city (2021; 62%), and 64% (2080) were men who likely
acquired HIV through sex with other men. At ART initiation,
median age was 38 years [interquartile range (IQR) 33–44],
median CD4 cell count was 222 cells/mm3 (124–321) and
median VL was 4.95 log10 copies/ml (4.43–5.41). Most
individuals (1985; 61%) started 1 NNRTI+2 NRTI, 37%
(1210) started 1 PI/r + 2 NRTI and 2% (63) started 1
integrase inhibitor + 2 NRTI. The most frequently used
drug regimens were efavirenz+tenofovir+emtricitabine
(932; 29%), efavirenz+lamivudine+zidovudine (319; 10%)
and lopinavir/ritonavir+lamivudine+zidovudine (177; 5%).
A total of 198 individuals (6%) had a VL >200 copies/ml
after 6 months of ART, and so experienced a lack of treat-
ment response using definition (i). An additional 313 indi-
viduals stopped or switched antiretroviral (ARV) drugs from
at least two drug classes (median [IQR] time to stop/switch:
105 [57–149] days), leading to 16% (511) experiencing a
lack of treatment response using definition (ii). A total of 39
individuals experienced both VL >200 copies/ml and made
an eligible ARV change. Of the individuals with lack of
treatment response according to definitions (i) and (ii), 84
out of 198 (42%) and 270 out of 511 (53%), respectively,
had achieved VL <200 copies/mL at month1 and/or at
month 3.
Of those who achieved VL <200 copies/ml on their
1 month VL value, only 4% did not have a treatment
response at 6 months using definition (i) (Figure 1),
compared to 8%, 23% and 24% among those with a
1 month VL of 1000–9999; 10,000–99,999 and
≥100,000 copies/ml, respectively (p < 0.001; chi-squared
Brima N et al. Journal of the International AIDS Society 2017, 20:21567
http://www.jiasociety.org/index.php/jias/article/view/21567 | http://dx.doi.org/10.7448/IAS.20.1.21567
2
test). When considering definition (ii), these figures were
14%, 16%, 34% and 62%, respectively (p < 0.001). Similar
trends were seen for the 3-month VL, with even greater
differences between groups in the probability of non-
response. The figures were 3%, 25%, 67%, 75% for defini-
tion (i) and 9%, 29%, 89%, 85% for definition (ii), respec-
tively (p < 0.001). For both the 1- and 3-month time points,
and for both endpoint definitions, the risk of treatment
non-response substantially increased at a VL cutoff of
10,000 copies/ml, with a further increase above
100,000 copies/ml for definition (ii).
Individuals with a VL ≥10,000 copies/ml after 1 month of
ART had 5.7 times the odds (OR = 5.7; 95% CI 3.6–9.0) of
treatment non-response by 6 months (definition (i)) com-
pared to those who had VL <10,000 copies/ml, and 4.2
times the odds using definition (ii) (OR = 4.2; 2.90–6.15),
see Table. After 3 months of ART, individuals with a VL
≥10,000 copies/ml had almost 51.2 times the odds
(OR = 51.2; 27.9–93.8) under definition (i) and 60-fold
increased odds using definition (ii) (OR = 59.8; 26.8–133.6)
to have treatment non-response at 6 months.
To assess the ability to predict treatment response, the
AIC was calculated based on logistic regression models in
which each measure (VL, change in VL) was modelled as
a continuous rather than a categorical variable (Table 1).
The results indicate that for either definition of
response, and for univariate or multivariate models,
the 3 month VL has the best predictive ability of the
measures considered. Conversely, CD4 count at 1 and
3 months did not predict non-response in multivariate
models. In addition, men who likely acquired HIV het-
erosexually (adjusted odds ratio [aOR] = 2.69 vs. men
who have sex with men CI 1.44–5.03, p = 0.002);
women (aOR = 1.97, CI 1.02–3.81; p = 0.044) and
those of black ethnicity (aOR = 1.85 vs. white; CI
1.01–3.40, p = 0.046) had higher odds of treatment
failure at six months using definition (i). Increasing age
(aOR = 0.98 per 1 year older; 95% CI 0.96–1.01;
p = 0.127), ethnicity others OR = 1.24, CI 0.62–2.57;
p = 0.545 and those on an NNRTI-containing regimen
(aOR = 1.05 vs. other; CI 0.69–1.59; p = 0.835) were not
significantly different.
The results of all sensitivity analyses were consistent with
the main findings.
Although the proportion of individuals starting ART in
the period 2000–2014 and not achieving an initial virologic
response was small, we identified subgroups at greater
risk. We found that most individuals with a VL
>10,000 copies/ml after 3 months of ART did not achieve
viral suppression at 6 months and their risk was much
greater than those with lower VL. A VL >10,000 copies/
ml at 3 months seems a reasonable criterion to identify
individuals for early intervention to increase the effective-
ness of treatment. A VL >10,000 copies/mL at one month
is a weak early warning sign that viral suppression will not
be achieved. While most people in this situation do still
achieve suppression at 6 months, this may be, at least in
part, because clinics are already starting to emphasize
good ART adherence and helping to address any identified
issues.
Besides showing that the best predictor of 6 month
treatment non-response is a VL at 3 months and that one
month VL is a less strong predictor, our results also suggest
that current VL levels are superior predictors to change in
VL from pre-ART levels. In other words, we suggest the
current VL measure is more important than considering
the speed of VL decline. Finally, the CD4 count had little
predictive ability over this early treatment period.
The considerably higher treatment non-response rates
seen in the highest 1 and 3 month VL categories under
definition (ii) compared to definition (i) suggests that clin-
icians are already successfully intervening in this group
through treatment changes before the 6-month time
point was reached. These early VL results are reported to
treating clinicians, who may be interpreting them as an
early measure of adherence and intervene accordingly.
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Nonetheless, the large effect sizes seen in this study sug-
gest that further intervention could be possible.
In previous studies, baseline VL has been shown to be
associated with the probability of achieving VL
<500 copies/ml [5–9]. Early VL measures have previously
been shown to be a good predictor of treatment failure by
6–12 months [3,4]. Furthermore, a handful of studies have
looked at relationships between the early viral response to
ART and longer-term viral response results after
6–12 months of ART [4,7–9]. Cozzi Lepri and colleagues
in 2001 [9] showed that 4 and 8 week VLs are strong
predictors of viral response over the first 24 weeks of ART
in a clinical cohort of patients starting ART. Raboud and
colleagues [4] found that VL measurement at 16 weeks is
predictive of virological success at 1 year of triple therapy
among patients in a clinical trial. However, these studies
were carried out pre-2000. In recent years, more effective
and better tolerated antiretroviral drugs have become
available. Integrase inhibitors have been shown to have
a very potent and rapid antiretroviral effect [11]; there-
fore, the usefulness of early VL measures to predict long-
term virological outcome may have changed for people
starting ART more recently.
In our analysis, we only included those with a suffi-
cient number of VL measurements. Therefore, we may
have excluded infrequent clinic attenders or those lost to
follow-up, for whom levels of treatment response may be
poorer. We did not have data for all participants on the
reasons for switching or stopping in our data set and so
we attempted to capture stopping due to perceived
treatment failure by using a definition that incorporated
major changes to the ART regimen. Our sample included
only a small number of people starting integrase inhibi-
tors which are now recommended as part of first-line
regimens [12], and so we were unable to examine
whether associations differed in this subgroup. Although
we have constructed a definition of switch for failure
based on advice from treating clinicians at the two parti-
cipating centres, it is possible that some of the switches
included under the definition (ii) of lack of treatment
response were for toxicity reasons, rather than virological
failure. We did not have data on transmitted drug resis-
tance, which is currently estimated to have a prevalence
of 7% in the UK [13]. This may have been an important
factor among those who never achieved virological sup-
pression. Finally, we also did not have information on
participants’ adherence.
Conclusions
Very early VL measures taken 1 and 3 months after the
start of ART could be a useful indicator of initial treatment
non-response. We suggest that a value >10,000 copies/ml
at 3 months identifies individuals at a high risk of non-
response at 6 months and should prompt specific interven-
tions, such as initiating adherence support strategies. This
criterion could also be used to select a population to test
candidate interventions, such as addition of an agent from
another class of ART.
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